Abstract

Cell adhesion molecule 1 (CADM1), initially identified as a tumor suppressor gene, has recently been reported to be ectopically expressed in primary adult T-cell leukemia-lymphoma (ATL) cells. We incorporated CADM1 into flow-cytometric analysis to reveal oncogenic mechanisms in human T-cell lymphotrophic virus type I (HTLV-I) infection by purifying cells from the intermediate stages of ATL development. We isolated CADM1- and CD7-expressing peripheral blood mononuclear cells of asymptomatic carriers and ATLs using multicolor flow cytometry. Fluorescence-activated cell sorted (FACS) subpopulations were subjected to clonal expansion and gene expression analysis. HTLV-I-infected cells were efficiently enriched in CADM1(+) subpopulations (D, CADM1(pos)CD7(dim) and N, CADM1(pos)CD7(neg)). Clonally expanding cells were detected exclusively in these subpopulations in asymptomatic carriers with high proviral load, suggesting that the appearance of D and N could be a surrogate marker of progression from asymptomatic carrier to early ATL. Further disease progression was accompanied by an increase in N with a reciprocal decrease in D, indicating clonal evolution from D to N. The gene expression profiles of D and N in asymptomatic carriers showed similarities to those of indolent ATLs, suggesting that these subpopulations represent premalignant cells. This is further supported by the molecular hallmarks of ATL, that is, drastic downregulation of miR-31 and upregulation of abnormal Helios transcripts. The CADM1 versus CD7 plot accurately reflects disease progression in HTLV-I infection, and CADM1(+) cells with downregulated CD7 in asymptomatic carriers have common properties with those in indolent ATLs.

Highlights

  • Human T-cell lymphotrophic virus type I (HTLV-I) is a human retrovirus that causes human T-cell lymphotrophic virus type I (HTLV-I)–associated diseases, such as adult T-cell leukemia–lymphoma (ATL), HTLV-I– associated myelopathy/tropical spastic paraparesis, and HTLV-I uveitis [1,2,3]

  • Expanding cells were detected exclusively in these subpopulations in asymptomatic carriers with high proviral load, suggesting that the appearance of D and N could be a surrogate marker of progression from asymptomatic carrier to early ATL

  • It takes several decades for HTLV-I–infected cells to reach the final stage of multistep oncogenesis, which is clinically recognized as aggressive ATL

Read more

Summary

Introduction

Human T-cell lymphotrophic virus type I (HTLV-I) is a human retrovirus that causes HTLV-I–associated diseases, such as adult T-cell leukemia–lymphoma (ATL), HTLV-I– associated myelopathy/tropical spastic paraparesis, and HTLV-I uveitis [1,2,3]. Authors' affiliations: 1Division of Molecular Therapy; 2Laboratory of Diagnostic Medicine, Division of Stem Cell Therapy; 3Department of Hematology/Oncology, Research Hospital; 4Clinical Laboratory, Research Hospital, Institute of Medical Science; and5Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/). 2% to 3% for females [4,5,6] It takes several decades for HTLV-I–infected cells to reach the final stage of multistep oncogenesis, which is clinically recognized as aggressive ATL

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call